Skip to main navigation

Skip to Content

Menu

About Cerevel
Our Programs
Our Science
- Our scientific strategy
- Our pipeline
Investor & Media
Careers
- Working at Cerevel Therapeutics
- Open positions
Contact Us

News & Announcements

News & Announcements

Year

Sep 06, 2022

Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Aug 12, 2022

Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock

Aug 12, 2022

Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes

Aug 10, 2022

Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

Aug 10, 2022

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

Aug 01, 2022

Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

Jul 25, 2022

Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022

Jun 15, 2022

Cerevel Therapeutics Announces Updates to its Board of Directors

May 25, 2022

Cerevel Therapeutics to Present at the Jefferies Healthcare Conference

May 10, 2022

Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18

Print

RSS Feeds

Email Alerts

Investor Contact

Search

Cerevel

About CerevelAbout Cerevel
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our ScienceOur Science
- Our scientific strategy
- Our pipeline
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- Darigabat
- CVL-231
- CVL-936
Investors & MediaInvestors & Media
- Overview
- News & Events
- Stock
- Financials
- Governance
- Resources
CareersCareers
- Working at Cerevel Therapeutics
- Open Positions
Contact Us

Facebook
Twitter
LinkedIn
YouTube

Cerevel

Terms of Use
Privacy Policy
FCOI
Early Access Program (EAP) Policy

© 2022 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of

Cerevel Therapeutics. All Rights Reserved.